Background: Psoriatic Arthritis (PsA) affects up to 30% of people with psoriasis 1 .
AB0744 DOES TIMING OF INITIATION OF ANTI-TNF AGENTS AFFECT THE QUALITY OF LIFE OUTCOMES IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS?
P.W. Background: Psoriatic arthritis (PsA) is associated with increased morbility and mortality and an accelerated atherosclerosis. Influence of anti-TNFalpha treatment (a widely used therapy in PsA) in subclinical atherosclerosis is still unclear. Objectives: The aim of this study was to evaluate subclinical atherosclerosis progression before, during and after 5 years of anti-TNFalpha treatment. Methods: Twenty-seven consecutive PsA patients were evaluated before TNF blockers therapy (T0), after 2 years (T1) and after 5 years (T2) of treatment. Subclinical atherosclerosis was evaluated through carotid duplex scanning, analyzing intima-media thickness (IMT) and flow-mediated dilation (FMD) . IMT values were expressed as IMT mean (cumulative mean of all the IMT mean in every analyzed carotid segment) and M-MAX (cumulative mean of all the higher IMT in every analyzed carotid segment). Response to therapy was studied by the evaluation of tender and swollen joints (Tj and Sj), DAS 28 (disease activity score), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Metrologic and metabolic data were collected. For the statistical evaluation of parameters over time (T0 vs T1, T1 vs T2) Student's T test for paired data was used. Results: From T0 to T1 a deterioration in IMT-mean and M-MAX (p<0.01) was
